Menu
2016

DR. LUCY GILBERT, RECIPIENT OF 2016 REVERSE FEASIBILITY CHAMPION AWARD

REVERSE FEASIBILITY 2.0 MASTER CLINICAL TRIAL AGREEMENTS NEGOTIATED WITH CANADA’S TOP CENTRE

2015

REVERSE FEASIBILITY PROGRAM 5 YEAR POST LAUNCH CONFIRMS 14 WEEK ACTIVATION TIME IN CANADA

SCIMEGA INKS 13TH PHASE I/II US-ONLY STUDY EXPANSION INTO CANADA IN 18 MONTHS

2014

SCIMEGA LAUNCHES “CANADA’S ONCOLOGY COMMUNITY KEY STAKEHOLDERS” PODCAST SERIES

2013

SCIMEGA EXPERIENCE NOW INCLUDES ALL DRUGABLE ONCOLOGY INDICATION

2012

SCIMEGA COMMITS TO HELPING SMALL AND MID SIZE BIOPHARMA OPTIMIZE ONCOLOGY TRIAL PERFORMANCE IN CANADA

2011

REVERSE FEASIBILITY PROGRAM 3 YEAR POST LAUNCH CONFIRMS 50% REDUCTION IN ACTIVATION TIME COMPARED TO INDUSTRY STANDARD

2009

REVERSE FEASIBILITY PILOT PROJECT ACTIVATES SITES IN 6 WEEKS

2008

THE REVERSE FEASIBILITY PROGRAM IS BORN

SCIMEGA’S MISSION AND PURPOSE : TO ATTRACT CUTTING EDGE CANCER TRIALS TO CANADA

2007
2003

SCIMEGA INKS 1ST CONTRACT WITH US BIOTECH ONCOLOGY DRUG DEVELOPPER

1998

SCIMEGA RESEARCH INKS CONTRACTS FOR ONCOLOGY TRIALS WITH EVERY MAJOR CANADIAN PHARMACEUTICAL AFFILIATE

1997

Sign up to Canadian Oncology Clinical Trial News

Receive updates from our blog, podcasts and resource library.

Search